Literature DB >> 31972607

Lack of Association Between the CCR5-delta32 Polymorphism and Neurodegenerative Disorders.

Kevin J Wojta1, Ariane H Ayer1, Eliana M Ramos1, Peter D Nguyen1, Anna M Karydas2, Jennifer S Yokoyama2, Joel Kramer2, Suzee E Lee2, Adam Boxer2, Bruce L Miller2, Giovanni Coppola1.   

Abstract

OBJECTIVE: Recent studies have suggested that diminished Ccr5 functioning has an effect on synaptic plasticity and hippocampal memory in mouse models. CCR5-delta32, a 32-bp frameshift deletion in human CCR5 encoding a nonfunctional receptor, has been reported to have a protective effect against human immunodeficiency virus infection but its role as a modifier of neurodegenerative disease has been minimally explored. We investigated whether the CCR5-delta32 polymorphism could have an effect in the context of human neurodegenerative diseases.
METHODS: We examined the frequency of the CCR5-delta32 polymorphism in a large and well-characterized cohort including 1425 patients with neurodegenerative dementias and 2032 controls.
RESULTS: We did not observe a significant association between the CCR5-delta32 polymorphism and any of the neurodegenerative diseases screened in this study. However, we observed an earlier age of onset among neurodegenerative disease patients carrying the CCR5-delta32 allele.
CONCLUSIONS: Although our findings were inconclusive, the earlier age of onset observed among neurodegenerative disease patients carrying the CCR5-delta32 allele suggests that the deletion may have a detrimental effect in the context of neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31972607      PMCID: PMC7365743          DOI: 10.1097/WAD.0000000000000367

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.357


  13 in total

1.  The chemokine receptor CCR5-Delta32 gene mutation is not protective against Alzheimer's disease.

Authors:  Onofre Combarros; Jon Infante; Javier Llorca; Nicolás Peña; Carlos Fernández-Viadero; José Berciano
Journal:  Neurosci Lett       Date:  2004-08-19       Impact factor: 3.046

2.  CCR2-64I polymorphism and CCR5Delta32 deletion in patients with Alzheimer's disease.

Authors:  Daniela Galimberti; Chiara Fenoglio; Carlo Lovati; Alberto Gatti; Ilaria Guidi; Eliana Venturelli; Gary R Cutter; Claudio Mariani; Gianluigi Forloni; Carla Pettenati; Pierluigi Baron; Giancarlo Conti; Nereo Bresolin; Elio Scarpini
Journal:  J Neurol Sci       Date:  2004-10-15       Impact factor: 3.181

3.  Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study.

Authors:  M W Smith; M Dean; M Carrington; C Winkler; G A Huttley; D A Lomb; J J Goedert; T R O'Brien; L P Jacobson; R Kaslow; S Buchbinder; E Vittinghoff; D Vlahov; K Hoots; M W Hilgartner; S J O'Brien
Journal:  Science       Date:  1997-08-15       Impact factor: 47.728

4.  The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates.

Authors:  H Choe; M Farzan; Y Sun; N Sullivan; B Rollins; P D Ponath; L Wu; C R Mackay; G LaRosa; W Newman; N Gerard; C Gerard; J Sodroski
Journal:  Cell       Date:  1996-06-28       Impact factor: 41.582

5.  Association between the polymorphism of CCR5 and Alzheimer's disease: results of a study performed on male and female patients from Northern Italy.

Authors:  Carmela Rita Balistreri; Maria Paola Grimaldi; Sonya Vasto; Florinda Listi; Martina Chiappelli; Federico Licastro; Domenico Lio; Calogero Caruso; Giuseppina Candore
Journal:  Ann N Y Acad Sci       Date:  2006-11       Impact factor: 5.691

6.  CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia.

Authors:  J He; Y Chen; M Farzan; H Choe; A Ohagen; S Gartner; J Busciglio; X Yang; W Hofmann; W Newman; C R Mackay; J Sodroski; D Gabuzda
Journal:  Nature       Date:  1997-02-13       Impact factor: 49.962

7.  Chemokines (RANTES and MCP-1) and chemokine-receptors (CCR2 and CCR5) gene polymorphisms in Alzheimer's and Parkinson's disease.

Authors:  Cecilia Huerta; Victoria Alvarez; Ignacio F Mata; Eliecer Coto; René Ribacoba; Carmen Martínez; Marta Blázquez; Luis M Guisasola; Carlos Salvador; Carlos H Lahoz; Joaquín Peña
Journal:  Neurosci Lett       Date:  2004-11-11       Impact factor: 3.046

8.  Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.

Authors:  Gero Hütter; Daniel Nowak; Maximilian Mossner; Susanne Ganepola; Arne Müssig; Kristina Allers; Thomas Schneider; Jörg Hofmann; Claudia Kücherer; Olga Blau; Igor W Blau; Wolf K Hofmann; Eckhard Thiel
Journal:  N Engl J Med       Date:  2009-02-12       Impact factor: 91.245

9.  CCR5 deficiency induces astrocyte activation, Abeta deposit and impaired memory function.

Authors:  Yong Kyoung Lee; Dong Hoon Kwak; Ki Wan Oh; Sang-Yoon Nam; Beom Jun Lee; Young Won Yun; Yun-Bae Kim; Sang Bae Han; Jin Tae Hong
Journal:  Neurobiol Learn Mem       Date:  2009-04-24       Impact factor: 2.877

10.  A global reference for human genetic variation.

Authors:  Adam Auton; Lisa D Brooks; Richard M Durbin; Erik P Garrison; Hyun Min Kang; Jan O Korbel; Jonathan L Marchini; Shane McCarthy; Gil A McVean; Gonçalo R Abecasis
Journal:  Nature       Date:  2015-10-01       Impact factor: 49.962

View more
  2 in total

Review 1.  CCR5 as a Coreceptor for Human Immunodeficiency Virus and Simian Immunodeficiency Viruses: A Prototypic Love-Hate Affair.

Authors:  Anna J Jasinska; Ivona Pandrea; Cristian Apetrei
Journal:  Front Immunol       Date:  2022-01-27       Impact factor: 7.561

Review 2.  Role of Chemokines in the Development and Progression of Alzheimer's Disease.

Authors:  Jakub Wojcieszak; Katarzyna Kuczyńska; Jolanta B Zawilska
Journal:  J Mol Neurosci       Date:  2022-07-12       Impact factor: 2.866

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.